Changchun Baimu Biotechnology

Changchun Baimu Biotechnology is a Chinese biopharmaceutical firm focused on the research, development, and commercialization of recombinant protein products. Based in the Changchun High-tech Industrial Development Zone, the company specializes in producing recombinant human serum albumin (rHSA) using a proprietary Pichia pastoris expression platform. This animal-derived-component-free (ADCF) technology provides a safer alternative to plasma-derived albumin for use in vaccines, cell therapies, and as a pharmaceutical excipient. Baimu Biotechnology operates GMP-certified facilities and aims to supply high-purity biological reagents to the global life sciences industry. Their products are designed to meet the rigorous standards required for clinical applications and large-scale biomanufacturing. The company's focus on high-expression systems allows for cost-effective production of essential biological stabilizers and growth factors.